## DEC 1 3 2012

## 510(k) SUMMARY

Device Name	Device Trade name	C	
Device Name	Steerable Guiding Sheath, Model	Common/classification name Introducer, Catheter	
	Adelante Destino	minodujor, Guinetor	
Address and	Manufacturer	Sterilization Site	
Registration #			
*	Oscor Inc.	1. International Sterilization	
	3816 De Soto Boulevard	Laboratory Inc. (ISL)	
-	Palm Harbor, FL 34683	217 Sampey Road, Groveland, FL 34736	
		2. Oscor DMB Sterilizer	
		3816 De Soto Boulevard, Palm	
		Harbor, FL 34683	
•		3. Oscor Caribe, LLC	
		Avenida Las Americas, Nave I-2	
		Santo Domingo, Dom. Republic	
Contact	Mila Doskocil	mdoskocil@oscor.com	
	V.P. of Regulatory Affairs & Quality	727-937-2511	
•	Assurance		
	FDA Registration #	FDA Registration #	
	1035166	1061927 (ISL)	
		1035166	
		3004785273	
Device Class	Introducers, catheters, are classified as Class II, Reg No. 870.1340, code DYB		
Type of 510k	Traditional		
Reason for 510k	Addition of indications into the Indications for Use statement.		
Predicate Device Information	Boston Scientific, Z flex 270 Steerable Sheath, K112541		
	Enpath Medical, Steerable Sheath, K061119		
	CryoCath Technologies, FlexCath Steerable Sheath, K081049		

### Labeling and Intended Use

Proposed IFU only with modified Indications for Use statement is attached.

#### **Previously cleared Indications for Use**

The Adelante Destino Steerable Guiding Sheath is intended to facilitate the intracardiac placement of diagnostic and therapeutic devices.

#### **Proposed Indications for Use:**

The Adelante Destino Steerable Guiding Sheath is intended for the introduction of diagnostic and therapeutic devices into the human vasculature, including but not limited to intracardiac, renal or other peripheral placements. Do not use this device for neural placements.

The **Indications** for Use statement is attached.

# Device Description, Modification and Comparison to Predicate devices

This is a modification to <u>Indications for Use statement only</u>. There was no change in the text of IFU and method of use.

There is no modification to the device itself. The Adelante Destino Steerable Guiding Sheath has been cleared in K120459 and will remain intact and no modification to product labels.

Modification of Indications for Use statement was in the addition of indications for placement into vasculature and renal arteries, but restricted to peripheral placements only and excluding neural placements. The reason for modification is explained in the Rationale and Evaluation document attached.

The use of Destino guiding sheath has been compared to the predicate devices and found comparable to:

Boston Scientific: Z flex 270 Steerable Sheath is indicated for use to facilitate transvenous introduction of diagnostic/therapeutic catheters into the vasculature and into the chambers of the heart.

Enpath Medical Steerable Sheath is intended to be used to facilitate the placement of interventional devices into the peripheral and coronary systems.

CryoCath Technologies: The FlexCath Steerable Sheath is intended for percutaneous catheter introduction into the vasculature and into the chambers of the heart. The sheath deflection facilitates catheter positioning.

Modification Statement	This labeling modification has not altered the fundamental technology and the intended use methods from the predicate devices.	
Substantial Equivalence	The additional indications for Adelante Destino Steerable Guiding Sheath described in this submission are, in our opinion, substantially equivalent to the predicate devices and other similar introducer/guiding sheaths in commercial distribution.	



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

Mila Doskocil Vice President of Regulatory Affairs & Quality Assurance Oscor Inc. 3816 De Soto Boulevard Palm Harbor, FL 34683

DEC 1 3 2012

Re: K122960

Trade/Device Name: Adelante Destino Steerable Guiding Sheath

Regulation Number: 21 CFR 870.1340 Regulation Name: Catheter Introducer

Regulatory Class: Class II Product Code: DYB

Dated: September 21, 2012 Received: September 25, 2012

#### Dear Mila Doskocil:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure -

## **Indications for Use Statement**

510k Number (if known) K122960

Device Name: Steerable Guiding Sheath, model Adelante Destino

The steerable guiding sheath, model **Adelante Destino** is intended for the introduction of diagnostic and therapeutic devices into the human vasculature, including but not limited to intracardiac, renal or other peripheral placements.

Do not use this device for neural placements.

Prescription Use X	OR	Over-The-Counter Use
(Per 21 CFR 801.109)	•	
(Optional Format 1-2-96)		
•		
(PLEASE DO NOT WRITE BELO	W THIS LINE – CO	ONTINUE ON ANOTHER PAGE IF
•	,	
NEEDED)		•
,		

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division Syn-Off

Division of Cardiovascular Devices

510(k) Number\_